Devyser has entered an agreement with Thermo Fisher Scientific to collaborate on obtaining U.S. Food and Drug Administration (FDA) approval for One Lambda™ Devyser Accept cfDNA, their…
Devyser has achieved a significant regulatory milestone with its first market registration from China’s National Medical Products Administration (NMPA) for Devyser Compact, an…
Devyser invites investors, analysts and media to a Capital Markets Day on Monday, November 25, 2024 at the company's headquarters in Årsta, Stockholm.
The program will include…
On Wednesday, October 30 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q3 2024 report (which will have been published earlier on October 30 at 07:30…
Devyser Diagnostics AB (publ) today announces that the company has terminated the liquidity guarantee agreement with Carnegie Investment Bank. The agreement expires on November 29,…
Devyser’s post-transplant products will be featured in 7 posters at the upcoming American Society of Histocompatibility and Immunogenetics (ASHI) meeting at Anaheim California in October,…
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large…
Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico Milano is valid for three years with the possibility of a one-year extension. The…
On Tuesday July 23 at 09:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q2 2024 report (which will have been published earlier on July 23 at 07.30 a.m. CET).…
Devyser has secured a tender for its NGS product, Devyser Thalassemia, which is designed for screening and confirmation of thalassemia, a hereditary blood disorder. The tender, with a…
